[E-Daily Reporter Kim Seung-kwon ] "Herrings has been selected as a partner for Luxembourg’s national disease management project. This achievement is believed to have been made possible thanks to the strong recommendation by Dr. Liners, Head of Health Technology at the Luxembourg Ministry of Economy, to the Ministry of Health and Welfare."

Nam Byung-ho, CEO of Herings, explained the outcome of the meeting with the Luxembourg government in these terms. With this, a South Korean healthcare company has emerged that will collaborate directly with the Luxembourg government.

The company is also on the verge of converting its existing Memorandum of Understanding (MOU) with the Emile Meirisch Hospital (CHEM) into a formal main contract that will drive actual revenue. Clinical trials to obtain European CE certification (Class IIa) for OstoCare are also set to begin in earnest under local leadership.

Herrings Collaborates with Luxembourg... The Significance of the Agreement

Herrings recently achieved tangible results after receiving its second official invitation to “Nexus 2026”—Luxembourg’s largest digital technology conference—following its first participation in 2024. The most notable development was that Dr. Liners, Head of Health Technology at the Luxembourg Ministry of the Economy, officially recommended Herings as the top priority partner in response to a request from the Ministry of Health and Welfare for recommendations on companies to participate in national policy initiatives. Based on this, a joint meeting was immediately arranged, attended by Tom, Chief of Staff at the Ministry of Health and Welfare, as well as representatives from the Ministry of the Economy and the four major local hospitals.

During the meeting, Herring’s core solutions—the Ostocare remote monitoring system for cancer patients and the patient-customized platform Healiary—were presented in detail. Top local officials and hospital leadership deemed these solutions essential for cancer patient care and expressed a strong willingness to collaborate.

CEO Nam stated, “This meeting yielded significant business value, as Herring’s business has been elevated from individual patient care to serving as the core software for national-level projects.”

Herring’s partnerships with major local hospitals have also entered a concrete monetization phase. The company has agreed with CHEM Hospital, a leading general hospital in Luxembourg, to transition from an existing MOU to a substantive formal contract and is currently reviewing the draft agreement in detail.

To obtain Ostocare CE Mark certification (Class IIa)—an essential gateway to entering the European market—CHEM Hospital has decided to take the lead in conducting clinical research. The company aims to complete the application for research funding by June of this year. Based on the results of this pivotal clinical trial, Herring plans to gradually expand the adoption of its solution to all four major hospitals in Luxembourg.

Herrings has also joined as an official partner in an international project to improve the diets of cancer patients, led by the Luxembourg School of Hotel and Tourism (EHTL) with joint participation from Italy and France. In collaboration with the Luxembourg Institute of Health (LIH), the company will establish the scientific basis for developing specialized foods for patients whose sense of taste and smell have been impaired by cancer treatment and will lead the design of clinical studies.

He emphasized, “Clinical data from the specialized foods developed in the future will be integrated with Herings’ Hilliery platform and provided as personalized, precision dietary services for patients.”

Why Luxembourg Is Taking an Interest in a Korean AI Company

Herrings has developed a personalized digital healthcare platform for cancer patients. CEO Nam graduated from Seoul National University and attended Michigan State University and Boston University. Drawing on his 12 years of experience designing cancer clinical trials at the National Cancer Center, CEO Nam founded Herrings in 2013. “I started the company with the desire to improve the quality of life for cancer patients, even if only slightly,” he said.

The company plans to evolve the platform into an integrated care platform for cancer patients in the future. Among its investors, the company with the largest stake is Cory Group, owned by President Lim Jong-yoon, the largest shareholder of DXVX, and it is also receiving strategic investments from entities such as #Kakao Healthcare.

In South Korea, the company recently agreed to collaborate on technology development with the SEERS TECHNOLOGY(458870). In Europe, it is pursuing a business partnership with the Luxembourg government. Although Luxembourg is a small country with a population of 660,000, it is also a wealthy nation with the world’s highest per capita gross domestic product (GDP). For the past five years, it has been fostering the space industry, AI, and CHA AI Healthkare as its next-generation growth engines. Europe as a whole is facing bottlenecks in its limited healthcare resources due to rapid aging and an increase in patients with chronic diseases; to overcome this, it has sought cooperation with South Korean companies that excel in information technology (IT).

In particular, Luxembourg hosts the annual NEXUS Luxembourg exhibition—a global AI and technology trade show—and has been expressing direct and indirect interest in and investment in Korean companies. Last year, Korean fintech companies including △CrossHub, △NC& Co., Ltd., △276 Holdings, △OneCup, △Credos Partners, and △Tredox participated in the event.

In the case of Herring, the company even received a letter of intent from Luxembourg’s Minister of the Economy. CEO Nam emphasized, “I’ve heard they’ve never written one like that before,” adding, “We received an unprecedented letter of intent from the Minister of the Economy, promising that officials from our government ministries would actively and continuously support us.”

Currently, a dedicated team for Herings has been formed at LuxInnovation. The reason for choosing Luxembourg is clear: its location at the heart of Europe makes it easy to expand into countries such as △France, △Germany, and △Belgium, and the government’s active support is a major advantage. Although the government does not invest directly, companies can receive institutional and administrative support, including △connections to investors, △provision of clinical research funds, and △visa issuance.

He noted, “The head of the health tech division is fully responsible for and assisting us,” and predicted, “By next year, our platform will expand across all of Europe.”

An official in the digital healthcare industry commented, “Securing credible clinical references from top-tier European medical institutions, such as CHEM Hospital in Luxembourg, and proactively obtaining CE certification is effectively equivalent to obtaining a ‘free pass’ to the single market of the 27 European Union (EU) member states,” “Herring’s strategic moves—simultaneously fostering direct cooperation with national government agencies and forging partnerships with leading medical institutions—will serve as a good role model for the global expansion of the domestic digital healthcare industry,” the source added.